Mologic - BIG in tiny Science Revenue and Competitors

Claim your profile

THURLEIGH, UK

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Mologic - BIG in tiny Science's estimated annual revenue is currently $15.5M per year.(i)
  • Mologic - BIG in tiny Science's estimated revenue per employee is $155,000

Employee Data

  • Mologic - BIG in tiny Science has 100 Employees.(i)
  • Mologic - BIG in tiny Science grew their employee count by 2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M350%N/AN/A
#2
$2.6M38719%$631.7MN/A
#3
$14M75-3%$81MN/A
#4
$49.2M0N/A$132.9MN/A
#5
$12.6M660%N/AN/A
#6
$513.8M331519%N/AN/A
#7
$8.4M54-11%N/AN/A
#8
$31.2M201-7%N/AN/A
#9
$15.2M980%N/AN/A
#10
$73.6M475-2%N/AN/A

keywords:N/A

N/A

Total Funding

100

Number of Employees

$15.5M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mologic - BIG in tiny Science News

2021-02-09 - Avacta Group plc announces commercial partnership with Mologic

Avacta Group plc announces commercial partnership with Mologic 09-02-2021 New partnership aims to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries. Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherape ...

2021-02-09 - Avacta Group plc announces commercial partnership with Mologic

Avacta Group plc announces commercial partnership with Mologic 09-02-2021 New partnership aims to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries. Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherape ...

2021-02-09 - Avacta Group plc announces commercial partnership with Mologic

Avacta Group plc announces commercial partnership with Mologic 09-02-2021 New partnership aims to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries. Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherape ...